Literature DB >> 17603758

The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatment.

M D Bóveda1, M L Couce, D E Castiñeiras, J A Cocho, B Pérez, M Ugarte, J M Fraga.   

Abstract

The response to tetrahydrobiopterin (BH4) in patients with phenylalanine hydroxylase (PAH, EC 1.14.16.1) deficiency (OMIM 261600) has been widely reported. Here we report results of the BH4 loading test (20 mg/kg per day) in a group of 36 patients with PAH deficiency and phenotype of mild hyperphenylalaninaemia (HPA), mild phenylketonuria (PKU) or classic PKU. The patients ranged from neonates aged 7-15 days, detected in the Newborn Screening Programme for PKU in the population of Galicia (NW Spain), to adults aged up to 32 years who had been receiving a low-phenylalanine (Phe) diet for a period of years. Ten of the 36 patients showed a reduction of more than 30% in plasma Phe levels within 24 h of BH4 loading (ranging from 33.7% to 90.2%, mean 59.2%, SD 19.8%). All the patients with mild HPA (100%) showed a positive response; 57% of patients with mild PKU (4 of 7) showed a positive response. Of particular interest were positive responses in two patients with classic PKU, and in one patient with mutations of the phenylalanine hydroxylase (PAH) gene that have not to date been reported to be BH4-responsive (p.S303A and p.G46S). BH4 treatment (5-8 mg/kg per day) was commenced in 9 of the 10 BH4-responsive patients. The observed responses to treatment argue for application of the BH4 loading test in all patients with HPA or PKU, independently of genotype, phenotype or age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17603758     DOI: 10.1007/s10545-007-0567-1

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  New insights in growth of phenylketonuric patients.

Authors:  María L Couce; Ipek Guler; Andrés Anca-Couce; Marta Lojo; Alicia Mirás; Rosaura Leis; Alejandro Pérez-Muñuzuri; José M Fraga; Francisco Gude
Journal:  Eur J Pediatr       Date:  2014-11-01       Impact factor: 3.183

2.  Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

Authors:  M L Couce; M D Bóveda; E Valerio; A Pérez-Muñuzuri; J M Fraga
Journal:  JIMD Rep       Date:  2011-09-06

Review 3.  Sapropterin dihydrochloride for phenylketonuria.

Authors:  Usha Rani Somaraju; Marcus Merrin
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

4.  Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria.

Authors:  Oriane Leuret; Magalie Barth; Alice Kuster; Didier Eyer; Loïc de Parscau; Sylvie Odent; Brigitte Gilbert-Dussardier; François Feillet; François Labarthe
Journal:  J Inherit Metab Dis       Date:  2012-03-03       Impact factor: 4.982

Review 5.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

6.  Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation.

Authors:  Jytte Bieber Nielsen; Karin E Nielsen; Flemming Güttler
Journal:  J Inherit Metab Dis       Date:  2010-02       Impact factor: 4.982

7.  Effect of BH(4) supplementation on phenylalanine tolerance.

Authors:  A Burlina; N Blau
Journal:  J Inherit Metab Dis       Date:  2008-12-09       Impact factor: 4.982

Review 8.  Phenylketonuria: translating research into novel therapies.

Authors:  Gladys Ho; John Christodoulou
Journal:  Transl Pediatr       Date:  2014-04

9.  Carbohydrate status in patients with phenylketonuria.

Authors:  María L Couce; Paula Sánchez-Pintos; Isidro Vitoria; María-José De Castro; Luís Aldámiz-Echevarría; Patricia Correcher; Ana Fernández-Marmiesse; Iria Roca; Alvaro Hermida; Miguel Martínez-Olmos; Rosaura Leis
Journal:  Orphanet J Rare Dis       Date:  2018-06-27       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.